Icahn Leaves Pool, Genzyme Shareholder No More
This article was originally published in The Pink Sheet Daily
Cambridge neighbor Biogen Idec, meanwhile, girds for a power struggle at its May annual meeting.
You may also be interested in...
Putting a “permanent for sale sign out on the front lawn” is not the appropriate way to run the biotech either, CEO Mullen maintains.
Billionaire investor Icahn asserts Biogen intentionally derailed a search for a buyer by refusing to allow interested parties to speak with its Tysabri partner, Elan.
Enzyme replacement therapy for Pompe disease recorded $62 million in sales in the quarter, representing the most rapid growth of any of the firm’s lysosomal products.